Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
02 August 2006Website:
http://www.anavex.comNext earnings report:
08 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | 7 min agoDividend
Analysts recommendations
Institutional Ownership
AVXL Latest News
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental and neuropsychiatric disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome, schizophrenia, and other central nervous system (CNS) diseases, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference being held June 27, 2024.
Anavex Life Sciences (AVXL) has been upgraded to a Zacks Rank #2 (Buy), indicating increased confidence in the company's earnings potential. This could lead to a rise in the stock price in the short run.
NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome, schizophrenia and other central nervous system (CNS) diseases, today announced that it will present at the 23rd Annual Needham Virtual Healthcare Conference, April 8 – 11, 2024. Christopher U Missling, PhD, President & Chief Executive Officer will present the Company scheduled at 8:45 AM (ET) on Monday, April 8th, 2024.
Anavex Life Sciences Corp. (AVXL) Q1 2024 Earnings Call Transcript
GSK's revenues benefit from strong growth across all segments, especially the Shingles and RSV vaccines. The company also issues fresh 2024 guidance for all its segments.
The average of price targets set by Wall Street analysts indicates a potential upside of 530.7% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
IKT, EGO, MDB, PD and AVXL have been added to the Zacks Rank #1 (Strong Buy) List on January 26, 2023.
Anavex Life Sciences (AVXL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Anavex (AVXL) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Anavex Life Sciences (NASDAQ:AVXL) shares plunged this week on mixed results from its Rett Syndrome clinical study but analysts at Dawson James still see the stock as a worthwhile investment. The company reported topline results from its Phase 2/3 EXCELLENCE study in pediatric Rett Syndrome which had enrolled 92 patients aged from five to 17 years.
- 1(current)
What type of business is Anavex Life Sciences?
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
What sector is Anavex Life Sciences in?
Anavex Life Sciences is in the Healthcare sector
What industry is Anavex Life Sciences in?
Anavex Life Sciences is in the Biotechnology industry
What country is Anavex Life Sciences from?
Anavex Life Sciences is headquartered in United States
When did Anavex Life Sciences go public?
Anavex Life Sciences initial public offering (IPO) was on 02 August 2006
What is Anavex Life Sciences website?
https://www.anavex.com
Is Anavex Life Sciences in the S&P 500?
No, Anavex Life Sciences is not included in the S&P 500 index
Is Anavex Life Sciences in the NASDAQ 100?
No, Anavex Life Sciences is not included in the NASDAQ 100 index
Is Anavex Life Sciences in the Dow Jones?
No, Anavex Life Sciences is not included in the Dow Jones index
When does Anavex Life Sciences report earnings?
The next expected earnings date for Anavex Life Sciences is 08 August 2024